
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11730797/publications.pdf Version: 2024-02-01



DALIL LLIMBURC

#	Article	IF	CITATIONS
1	Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use. Mayo Clinic Proceedings, 2022, 97, 101-109.	1.4	6
2	Provider-perceived barriers to patient adherence to colorectal cancer screening. Preventive Medicine Reports, 2022, 25, 101681.	0.8	7
3	Life-years gained resulting from screening colonoscopy compared with follow-up colonoscopy after a positive stool-based colorectal screening test. Preventive Medicine Reports, 2022, 26, 101701.	0.8	2
4	Impact of the Sessile Serrated Polyp Pathway on Predicted Colorectal Cancer Outcomes. , 2022, 1, 55-62.		1
5	Multicancer early detection: International summit to Clarify the Roadmap. Cancer, 2022, 128, 859-860.	2.0	0
6	Factors Associated With Clinician Recommendations for Colorectal Cancer Screening Among Average-Risk Patients: Data From a National Survey. Preventing Chronic Disease, 2022, 19, E19.	1.7	4
7	Associations between tissueâ€based CD3+ Tâ€lymphocyte count and colorectal cancer survival in a prospective cohort of older women. Molecular Carcinogenesis, 2021, 60, 15-24.	1.3	1
8	Impact of screening and followâ€up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRCâ€AIM microsimulation model. Cancer Medicine, 2021, 10, 2855-2864.	1.3	4
9	Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45–49 Year-Olds: A Cross-Sectional Study. Cancer Prevention Research, 2021, 14, 489-496.	0.7	26
10	Recent trends in colorectal cancer screening methods based on Medicare claims data. Current Medical Research and Opinion, 2021, 37, 605-607.	0.9	7
11	Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia. Cancer Prevention Research, 2021, 14, 573-580.	0.7	16
12	National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences. Cancer Prevention Research, 2021, 14, 603-614.	0.7	27
13	Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model. Current Medical Research and Opinion, 2021, 37, 1005-1010.	0.9	5
14	Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes. Cancer Prevention Research, 2021, 14, 845-850.	0.7	8
15	Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a large, nationally insured cohort. International Journal of Colorectal Disease, 2021, 36, 2471-2480.	1.0	11
16	An examination of socioeconomic and racial/ethnic disparities in the awareness, knowledge and utilization of three colorectal cancer screening modalities. SSM - Population Health, 2021, 14, 100780.	1.3	5
17	Patient preferences on general health and colorectal cancer screening decision-making: Results from a national survey. Patient Education and Counseling, 2021, , .	1.0	2
18	Barriers to utilization of three colorectal cancer screening options – Data from a national survey. Preventive Medicine Reports, 2021, 24, 101508.	0.8	12

#	Article	IF	CITATIONS
19	Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biology and Therapy, 2021, 22, 544-553.	1.5	6
20	Initial validation of a self-report questionnaire based on the Theoretical Domains Framework: determinants of clinician adoption of a novel colorectal cancer screening strategy. Implementation Science Communications, 2021, 2, 119.	0.8	1
21	Colorectal cancer screening completion: An examination of differences by screening modality. Preventive Medicine Reports, 2020, 20, 101202.	0.8	9
22	Comparison of Tissue-Based Molecular Markers in Younger versus Older Patients with Colorectal Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1570-1576.	1.1	4
23	Multitarget Stool DNA for Average Risk Colorectal Cancer Screening. Gastrointestinal Endoscopy Clinics of North America, 2020, 30, 553-568.	0.6	7
24	Healthcare Provider Perspectives on Lowering Colorectal Cancer Screening Initiation Age to 45 Years: Results From a Survey of Clinicians in the U.S Cancer Control, 2020, 27, 107327482097711.	0.7	3
25	Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model. PLoS ONE, 2020, 15, e0244431.	1.1	18
26	Well-Being Champion Impact on Employee Engagement, Staff Satisfaction, and EmployeeÂWell-Being. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 106-115.	1.2	6
27	A Randomized Controlled Trial in the Evaluation of a Novel Stress Management Tool: A Lounge Chair Experience. Global Advances in Health and Medicine, 2019, 8, 216495611989259.	0.7	1
28	Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development. EBioMedicine, 2019, 49, 145-156.	2.7	8
29	Marine omegaâ€3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). International Journal of Cancer, 2019, 145, 380-389.	2.3	22
30	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 696-703.	1.1	11
31	Chemoprevention of colorectal cancer: aspirin and beyond. Clinical Advances in Hematology and Oncology, 2018, 16, 552-554.	0.3	Ο
32	Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer Prevention Research, 2017, 10, 345-354.	0.7	35
33	Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 622-631.	1.1	68
34	Doubleâ€blind, randomized phase 3 trial of lowâ€dose 13â€cis retinoic acid in the prevention of second primaries in head and neck cancer: Longâ€term followâ€up of a trial of the Eastern Cooperative Oncology Groupâ€ACRIN Cancer Research Group (C0590). Cancer, 2017, 123, 4653-4662.	2.0	24
35	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial NO147. International Journal of Cancer, 2016, 139, 986-995.	2.3	16
36	Gastrointestinal Neoplasia: Current Perspectives and Emerging Frontiers. Gastroenterology Clinics of North America, 2016, 45, xi-xii.	1.0	1

#	Article	IF	CITATIONS
37	Common variants in the obesity-associated genes FTO and MC4R are not associated with risk of colorectal cancer. Cancer Epidemiology, 2016, 44, 1-4.	0.8	12
38	Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ, The, 2016, 355, i6188.	3.0	66
39	Socioeconomic Inequalities in the Utilization of Colorectal Stents for the Treatment of Malignant Bowel Obstruction. Digestive Diseases and Sciences, 2016, 61, 1669-1676.	1.1	4
40	Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. Mayo Clinic Proceedings, 2016, 91, 71-80.	1.4	20
41	Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women's Health Study. Modern Pathology, 2016, 29, 516-527.	2.9	65
42	Tumor Budding in Colorectal Carcinoma. American Journal of Surgical Pathology, 2015, 39, 1340-1346.	2.1	95
43	Accuracy of urea breath test in <i>Helicobacter pylori</i> infection: Meta-analysis. World Journal of Gastroenterology, 2015, 21, 1305.	1.4	154
44	Aspirin Prevents Colorectal Cancer by Normalizing EGFR Expression. EBioMedicine, 2015, 2, 447-455.	2.7	31
45	Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 713-719.	1.1	10
46	Association between Body Mass Index and Mortality for Colorectal Cancer Survivors: Overall and by Tumor Molecular Phenotype. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1229-1238.	1.1	44
47	Circulating Prostaglandin Biosynthesis in Colorectal Cancer and Potential Clinical Significance. EBioMedicine, 2015, 2, 165-171.	2.7	24
48	Metformin Does Not Reduce Markers of Cell Proliferation in Esophageal Tissues of Patients With Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2015, 13, 665-672.e4.	2.4	42
49	Hereditary Colorectal Cancer Syndromes: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk–Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guidelines. Journal of Oncology Practice, 2015, 11, e437-e441.	2.5	35
50	Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival. Gastroenterology, 2015, 148, 77-87.e2.	0.6	342
51	CT Colonography for the Detection of Nonpolypoid Adenomas: Sensitivity Assessed With Restricted National CT Colonography Trial Criteria. American Journal of Roentgenology, 2014, 203, W614-W622.	1.0	7
52	Associations between Cigarette Smoking, Hormone Therapy, and Folate Intake with Incident Colorectal Cancer by TP53 Protein Expression Level in a Population-Based Cohort of Older Women. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 350-355.	1.1	11
53	Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. Journal of the National Cancer Institute, 2014, 106, .	3.0	140
54	Associations Between Colorectal Cancer Molecular Markers and Pathways With Clinicopathologic Features in Older Women. Gastroenterology, 2013, 145, 348-356.e2.	0.6	49

#	Article	lF	CITATIONS
55	Reply. Clinical Gastroenterology and Hepatology, 2013, 11, 1209-1210.	2.4	2
56	Bisphosphonates Are Associated With Reduced Risk of Colorectal Cancer: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2013, 11, 232-239.e1.	2.4	21
57	Population Pharmacokinetic Model for Cancer Chemoprevention With Sulindac in Healthy Subjects. Journal of Clinical Pharmacology, 2013, 53, 403-412.	1.0	17
58	Noncathartic CT Colonography: Image Quality Assessment and Performance and in a Screening Cohort. American Journal of Roentgenology, 2013, 201, 787-794.	1.0	24
59	Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial N0147. Journal of Clinical Oncology, 2013, 31, 2016-2023.	0.8	49
60	Antidiabetic Medications and the Risk of Colorectal Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2258-2268.	1.1	81
61	Associations Between Intake of Folate and Related Micronutrients with Molecularly Defined Colorectal Cancer Risks in the Iowa Women's Health Study. Nutrition and Cancer, 2012, 64, 899-910.	0.9	33
62	The National CT Colonography Trial: Assessment of Accuracy in Participants 65 Years of Age and Older. Radiology, 2012, 263, 401-408.	3.6	36
63	Postmenopausal Hormone Therapy and Colorectal Cancer Risk in Relation to Somatic <i>KRAS</i> Mutation Status among Older Women. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 681-684.	1.1	25
64	Cigarette Smoking and Colorectal Cancer Risk by KRAS Mutation Status Among Older Women. American Journal of Gastroenterology, 2012, 107, 782-789.	0.2	32
65	Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut, 2012, 61, 1299-1305.	6.1	36
66	A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E2 in Patients With Barrett's Esophagus. Gastroenterology, 2012, 143, 917-926.e1.	0.6	58
67	Randomized controlled trial of acitretin versus placebo in patients at highâ€risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer, 2012, 118, 2128-2137.	2.0	69
68	A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147 Journal of Clinical Oncology, 2012, 30, 446-446.	0.8	0
69	Prevalence of Alterations in DNA Mismatch Repair Genes in Patients With Young-Onset Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2011, 9, 497-502.	2.4	65
70	Alcohol Intake and Colorectal Cancer Risk by Molecularly Defined Subtypes in a Prospective Study of Older Women. Cancer Prevention Research, 2011, 4, 2035-2043.	0.7	17
71	Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Research and Treatment, 2011, 126, 149-155.	1.1	82
72	Randomized Phase II Trial of Sulindac, Atorvastatin, and Prebiotic Dietary Fiber for Colorectal Cancer Chemoprevention. Cancer Prevention Research, 2011, 4, 259-269.	0.7	60

#	Article	IF	CITATIONS
73	Genes involved with folate uptake and distribution and their association with colorectal cancer risk. Cancer Causes and Control, 2010, 21, 597-608.	0.8	26
74	A Candidate Gene Study of Folate-Associated One Carbon Metabolism Genes and Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1812-1821.	1.1	36
75	Genetic Variability in the <i>MTHFR</i> Gene and Colorectal Cancer Risk Using the Colorectal Cancer Family Registry. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 89-100.	1.1	38
76	Use of Folic Acid–Containing Supplements after a Diagnosis of Colorectal Cancer in the Colon Cancer Family Registry. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2023-2034.	1.1	18
77	Case–Control Study of Overweight, Obesity, and Colorectal Cancer Risk, Overall and by Tumor Microsatellite Instability Status. Journal of the National Cancer Institute, 2010, 102, 391-400.	3.0	162
78	Cigarette Smoking and Colorectal Cancer Risk by Molecularly Defined Subtypes. Journal of the National Cancer Institute, 2010, 102, 1012-1022.	3.0	261
79	Serum Cytokine Analysis in a Positive Chemoprevention Trial: Selenium, Interleukin-2, and an Association with Squamous Preneoplastic Disease. Cancer Prevention Research, 2010, 3, 810-817.	0.7	5
80	Body Size and Incident Colorectal Cancer: A Prospective Study of Older Women. Cancer Prevention Research, 2010, 3, 1608-1620.	0.7	51
81	Prospective Study Reveals Associations Between Colorectal Cancer and Type 2 Diabetes Mellitus or Insulin Use in Men. Gastroenterology, 2010, 139, 1138-1146.	0.6	118
82	Serum Insulin, Glucose, Indices of Insulin Resistance, and Risk of Prostate Cancer. Journal of the National Cancer Institute, 2009, 101, 1272-1279.	3.0	120
83	Glycemic response of type 2 diabetics to sweetened dried cranberries. FASEB Journal, 2009, 23, 900.6.	0.2	0
84	Efficacy of Antioxidant Supplementation in Reducing Primary Cancer Incidence and Mortality: Systematic Review and Meta-analysis. Mayo Clinic Proceedings, 2008, 83, 23-34.	1.4	155
85	IGF-I, IGFBP-3, and IGF-I/IGFBP-3 Ratio: No Association with Incident Colorectal Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1832-1834.	1.1	14
86	Young-Onset Colorectal Cancer in Patients With No Known Genetic Predisposition. Medicine (United) Tj ETQq	0 0 0 _{0.g} BT /	Overlock 107
87	Accuracy of CT Colonography for Detection of Large Adenomas and Cancers. New England Journal of Medicine, 2008, 359, 1207-1217.	13.9	971
88	Comparative Bioavailability of Sulindac in Capsule and Tablet Formulations. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 674-679.	1.1	13
89	Effect of Slice Thickness and Primary 2D Versus 3D Virtual Dissection on Colorectal Lesion Detection at CT Colonography in 452 Asymptomatic Adults. American Journal of Roentgenology, 2007, 189, 672-680.	1.0	72
90	Association of Aspirin and Nonaspirin Nonsteroidal Anti-inflammatory Drugs With Cancer Incidence and Mortality. Journal of the National Cancer Institute, 2007, 99, 881-889.	3.0	76

#	Article	IF	CITATIONS
91	CYTOTOXIC PROPERTIES OF DIOSPYROS SEYCHELLARUM EXTRACT. Journal of Toxicological Sciences, 2007, 32, 487-493.	0.7	1
92	Assessing Attitudes Toward Laxative Preparation in Colorectal Cancer Screening and Effects on Future Testing: Potential Receptivity to Computed Tomographic Colonography. Mayo Clinic Proceedings, 2007, 82, 666-671.	1.4	55
93	Assessing Attitudes Toward Laxative Preparation in Colorectal Cancer Screening and Effects on Future Testing: Potential Receptivity to Computed Tomographic Colonography. Mayo Clinic Proceedings, 2007, 82, 666-671.	1.4	65
94	A high-throughput 3-parameter flow cytometry-based cell death assay. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2007, 71A, 170-173.	1.1	14
95	Colorectal cancer screening education: Developing a competency-based curriculum for medical training programs. Journal of Cancer Education, 2007, 22, 206-207.	0.6	0
96	Insulin, Glucose, Insulin Resistance, and Incident Colorectal Cancer in Male Smokers. Clinical Gastroenterology and Hepatology, 2006, 4, 1514-1521.	2.4	79
97	Gene Expression Differences in Normal Esophageal Mucosa Associated with Regression and Progression of Mild and Moderate Squamous Dysplasia in a High-Risk Chinese Population. Cancer Research, 2006, 66, 6851-6860.	0.4	27
98	Selenomethionine Treatment Does Not Alter Gene Expression in Normal Squamous Esophageal Mucosa in a High-Risk Chinese Population. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1046-1047.	1.1	4
99	Nonsteroidal Anti-inflammatory Drugs and Subsite-Specific Colorectal Cancer Incidence in the Iowa Women's Health Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1785-1790.	1.1	60
100	Clinically Confirmed Type 2 Diabetes Mellitus and Colorectal Cancer Risk: A Population-Based, Retrospective Cohort Study. American Journal of Gastroenterology, 2006, 101, 1872-1879.	0.2	129
101	Randomized, Placebo-Controlled, Esophageal Squamous Cell Cancer Chemoprevention Trial of Selenomethionine and Celecoxib. Gastroenterology, 2005, 129, 863-873.	0.6	99
102	Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 133-7.	1.1	65
103	Colorectal cancer chemoprevention. Chinese Journal of Digestive Diseases, 2004, 5, 7-11.	1.1	4
104	Cigarette smoking and colorectal cancer: Long-term, subsite-specific risks in a cohort study of postmenopausal women. Clinical Gastroenterology and Hepatology, 2003, 1, 202-210.	2.4	42
105	Prospective Evaluation of Fecal Calprotectin As A Screening Biomarker for Colorectal Neoplasia. American Journal of Gastroenterology, 2003, 98, 2299-2305.	0.2	55
106	Cigarette smoking and colorectal cancer: Long-term, subsite-specific risks in a cohort study of postmenopausal women. Clinical Gastroenterology and Hepatology, 2003, 1, 202-210.	2.4	42
107	Helicobacter pylori seropositivity and colorectal cancer risk: a prospective study of male smokers. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1095-9.	1.1	32
108	Immunodiscrimination of colorectal neoplasia using MUC1 antibodies: discrepant findings in tissue versus stool. Digestive Diseases and Sciences, 2000, 45, 494-499.	1.1	13

#	Article	IF	CITATIONS
109	Fecal Calprotectin Levels Predict Colorectal Inflammation Among Patients With Chronic Diarrhea Referred for Colonoscopy. American Journal of Gastroenterology, 2000, 95, 2831-2837.	0.2	148
110	Correlation of Trunk Muscle Strength With Age in Children 5 to 18 Years Old. Mayo Clinic Proceedings, 1996, 71, 1047-1054.	1.4	40
111	A Useful Technique for Measurement of Back Strength in Osteoporotic and Elderly Patients. Mayo Clinic Proceedings, 1991, 66, 39-44.	1.4	60